Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)
Kimmick G, Cirrincione C, Duggan D, Bhalla K, Robert N, Berry D, Norton L, Lemke S, Henderson I, Hudis C, Winer E, On Behalf of the Cancer and Leukemia Group B. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Research And Treatment 2008, 113: 479-490. PMID: 18306034, PMCID: PMC4217205, DOI: 10.1007/s10549-008-9943-2.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCombined Modality TherapyCyclophosphamideDisease ProgressionDoxorubicinFemaleFluorouracilFollow-Up StudiesHumansMastectomyMethotrexateMiddle AgedNeoadjuvant TherapyNeoplasm StagingRadiotherapy, AdjuvantSurvival AnalysisConceptsStage III breast cancerBreast cancerNeoadjuvant doxorubicinClinical responseLymph nodesClinical stage III breast cancerAdequate organ functionClinical response rateComplete clinical responseInvolved lymph nodesPositive lymph nodesAdvanced breast cancerPathologic complete responsePhase II trialHazard of deathLong-term resultsLong-term survivalAdjuvant chemotherapyAdjuvant cyclophosphamideMedian followII trialNeoadjuvant treatmentMultimodality treatmentOverall survivalComplete response